Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

View Full Paper

Ask AI

Bookmark

Tirzepatide significantly reduces the apnea-hypopnea index, with a treatment difference of −20.0 events per hour.
In trial 1, the mean AHI improved from baseline by −25.3 events per hour with tirzepatide compared to −5.3 with placebo.
Double-blind, randomized controlled trials compared tirzepatide to placebo over 52 weeks for changes in AHI and body weight outcomes across two groups receiving different treatments at baseline. The findings indicate that elevated hsCRP levels and systolic blood pressure were also reduced with tirzepatide therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomized trial shows tirzepatide reduces apnea-hypopnea index in adults with obesity, suggesting its potential as a treatment.

Malhotra et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark